Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2012. The report details a specific corporate action regarding share repurchases executed on September 14, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,750,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,441.5 pence per share; lowest price paid was 1,413.5 pence per share.
- Treasury Holdings (Settled): 514,715,427 shares (9.41% of total issued share capital).
- Treasury Holdings (Including Unsettled): 519,665,427 shares (10.48% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,957,920,825 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,750,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.48% when including unsettled purchases. The filing does not provide comparative financial data to assess changes in operating performance versus prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (514,715,427 settled vs. 519,665,427 including unsettled) for accurate voting rights calculations.
- Confirm the denominator for disclosure thresholds is 4,957,920,825 shares (excluding Treasury).
- Review the price paid per share (1,413.5 to 1,441.5 pence) against market prices on September 14, 2012.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings.